Nanobiotix Reports First Positive Phase 2 Data for NBTXR3 in Inoperable Stage 3 Lung Cancer

Nanobiotix ( (NBTX) ) has provided an update.

On March 30, 2026, Nanobiotix announced that Johnson & Johnson presented first data from the CONVERGE Phase 2 randomized trial of its nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer at the 2026 European Lung Cancer Conference. The Johnson & Johnson–sponsored study reported that intratumoral administration of JNJ-1900 followed by chemoradiation and consolidative immunotherapy showed an acceptable safety profile with no serious treatment-emergent adverse events and did not disrupt patients’ ability to continue planned therapy.

Early efficacy results in seven patients at first disease evaluation after concurrent chemoradiotherapy, before anti-PD-L1 treatment, showed a 71.4% objective response rate and 100% disease control, outperforming a benchmark objective response range of 45% to 50%. The data reinforce Nanobiotix’s strategy to position NBTXR3 as a potentially first-in-class, broadly scalable radioenhancer across solid tumors and support the value of its global co-development and commercialization partnership with Johnson & Johnson, potentially strengthening the company’s standing in the oncology innovation landscape and its prospects in lung cancer indications.

The most recent analyst rating on (NBTX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering physics-based nanotherapeutic approaches for oncology and other major diseases. Headquartered in Paris with a presence in Cambridge, Mass., it develops nanoparticle-based radioenhancers such as JNJ-1900 (NBTXR3), backed by more than 30 umbrella patents covering platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.

Founded in 2003 and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix focuses on leveraging radiotherapy-activated nanoparticles to enhance tumor cell destruction and stimulate immune responses. The company advances its lead asset NBTXR3 through internal programs and collaborations, including a global Phase 3 head and neck cancer trial and partnered development with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Average Trading Volume: 43,702

Technical Sentiment Signal: Buy

Current Market Cap: $1.47B

For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.